equine conjugated estrogens / Generic mfg. - LARVOL DELTA

Chemoselective halogenation of premarineosin A for next-generation antimalarial development. (PubMed, Org Biomol Chem) - "Biological evaluation revealed that all halogenated analogs retained potent antiplasmodial activity against both chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) Plasmodium falciparum strains. Although the molecular target of premarineosin A remains unknown, these findings demonstrate that C12 halogenation is potent in both parasite backgrounds. Collectively, these results establish late-stage C12 halogenation as an operationally efficient strategy for diversifying premarineosin A and demonstrate that subtle halogen substitution can modulate the antimalarial profile of this scaffold, providing a foundation for the future development of premarineosin-derived antiplasmodial agents."

Journal • Infectious Disease

Chemoselective Halogenation of Premarineosin A for Next-Generation Antimalarial Development. (PubMed, bioRxiv) - "Premarineosin A undergoes rapid, chemoselective C12 halogenation under mild conditions, providing brominated, chlorinated, fluorinated, and iodinated analogs. These derivatives retained potent antiplasmodial activity against both chloroquine-sensitive and -resistant Plasmodium falciparum strains and displayed smaller reductions in potency against the resistant strain than the parent compound."

Journal • Infectious Disease

Incidence of endometrial cancer among postmenopausal women using vaginal estrogen compared to estrogen and progestin combination hormone therapy. (PubMed, Menopause) - "Rates of endometrial cancer among women using low and high-dose vaginal estrogens were comparable to rates among women using EPT."

Journal • Endometrial Cancer • Gynecology • Oncology • Solid Tumor

PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: University of Pennsylvania | Trial completion date: May 2026 ➔ May 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Cardiovascular • Nephrology • Reperfusion Injury • Transplantation

Metabolic engineering and late-stage functionalization expand the chemical space of the antimalarial premarineosin A. (PubMed, Commun Chem) - "In this structure-activity relationship study of premarineosin A, we accessed a suite of analogs, including a C12-brominated derivative with nanomolar potency (EC50 < 5 nM). This work establishes (-)-premarineosin A as a tractable and evolvable antimalarial scaffold, demonstrating how chemical biology approaches can unlock structural and pharmacological space from complex microbial metabolites."

Journal • Infectious Disease

Topical Estrogen for Skin-Aging: A Systematic Review of Safety and Efficacy. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Dermatology • Dermatopathology

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Mackay Memorial Hospital | Trial completion date: Jun 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Overactive Bladder

Effects of Treatment With Premarin Alone and the Combination of Premarin + Beclomethasone in Vaginal Involvement of GVHD After Hematopoietic Stem Cell Transplantation. (PubMed, Transplant Proc) - "The combination of Premarin and Clobetasol is more effective than Premarin alone, particularly in cases of vaginal tightness. Other symptoms may be associated with atrophic manifestations."

Journal • Bone Marrow Transplantation • Fibrosis • Graft versus Host Disease • Immunology • Inflammation • Transplantation

PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: University of Pennsylvania | Trial completion date: Jan 2025 ➔ May 2026 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Cardiovascular • Nephrology • Reperfusion Injury • Transplantation

Effects of Huluan decotion on cyclophosphamide-induced autoimmune premature ovarian failure in murine models. (PubMed, J Tradit Chin Med) - "HLD effectively treats POF induced with cyclophosphamide in mice by enhancing expressions of Wnt4, β-Catenin and FOXL2."

Journal • Preclinical • Endocrine Disorders • Immunology • Women's Health • CTNNB1 • FOXL2

Advancing (-)-Premarineosin A as a Potent Antimalarial Therapeutic via Metabolic Engineering and Late-Stage Derivatization. (PubMed, bioRxiv) - "One promising contender is the natural product premarineosin A, an intermediate of the marineosin biosynthetic pathway that exhibits potent and selective antimalarial activity against both chloroquine-sensitive and multi-drug-resistant Plasmodium strains. Late-stage C-H bromination of the B-ring resulted in a highly potent (EC 50 < 5 nM) antimalarial compound with low cytotoxicity. These findings report progress toward the sustainable access of (-)-premarineosin A and the first structure-activity relationship study for this unique scaffold in the search for improved antimalarial therapeutics."

Journal • Infectious Disease • Malaria

Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. (PubMed, PLoS Med) - P4 | "In these KEEPS Continuation analyses, there were no long-term cognitive effects of short-term exposure to mHT started in early menopause versus placebo. These data provide reassurance about the long-term neurocognitive safety of mHT for symptom management in healthy, recently postmenopausal women, while also suggesting that mHT does not improve or preserve cognitive function in this population."

Clinical • Journal • Observational data

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Mackay Memorial Hospital | N=200 ➔ 300

Enrollment change • Overactive Bladder

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Mackay Memorial Hospital

New P4 trial • Overactive Bladder

Drugs for menopausal symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration. (PubMed, Hum Genet) - "Cisplatin-induced acute kidney injury (CP-AKI) is a common complication in cancer patients. Drug prediction and molecular docking were further used to propose that drugs targeting TACSTD2 may have therapeutic potential in CP-AKI, such as parthenolide, progesterone, premarin, estradiol and rosiglitazone. Our findings suggest a significant association between ferroptosis and the development of CP-AKI, with TACSTD2 playing a crucial role in modulating ferroptosis, which provides novel perspectives on the pathogenesis and treatment of CP-AKI."

Journal • Acute Kidney Injury • Nephrology • Oncology • Renal Disease • HMGB1 • IRF6 • TACSTD2

Establishing a Rationale for Compounding Hormone Replacement Therapy. (PubMed, Int J Pharm Compd) - "Premarin is no longer at the top of the heap, and there are topical, commercial products that contain bioidentical estradiol, and capsules that contain the same progesterone that we use. Our compounding advantage comes from our abilities to prepare unique patient-specific products, and, very importantly, from our growing understanding of hormone receptors; we now know there are two main estrogen receptors, 1) estrogen receptor alpha and 2) estrogen receptor beta, and the growing knowledge base associated with the discovery of estrogen receptor beta is quite significant."

Journal • ER

Physical energies for the management of genitourinary syndrome of menopause: An overview of a systematic review and network meta-analysis. (PubMed, Int J Gynaecol Obstet) - "Several gaps in the use of physical energy for managing GSM still need to be addressed. The small number of blind clinical trials made the results fragile."

Journal • Retrospective data • Review • Sexual Disorders • Women's Health

Effects of estrogen and raloxifene on synaptic density in the hippocampal CA1 region of ovariectomized rats. (PubMed, Clinics (Sao Paulo)) - "The present data suggest that the raloxifene effect may be lower than that of estrogen, even early or late treatment, on synaptic density in the hippocampus."

Journal • Preclinical • Anesthesia

Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial. (PubMed, Menopause) - "There was no evidence of cardiovascular and/or metabolic benefits or adverse effects associated with 4 years use of oral or transdermal forms of hormone therapy by recently menopausal women with good cardiovascular health after 10 years."

Journal • Cardiovascular • Diabetes • Metabolic Disorders

PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Nephrology • Reperfusion Injury • Transplantation

Association Between the Route of Administration and Formulation of Estrogen Therapy and Hypertension Risk in Postmenopausal Women: A Prospective Population-Based Study. (PubMed, Hypertension) - "Oral estrogen-only HT use was associated with an increased risk of hypertension in women. In women using estrogen-only HT, nonoral estradiol at the lowest dose and for the shortest time-period is associated with the lowest risk of hypertension."

Journal • Cardiovascular • Hypertension

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection (clinicaltrials.gov) - P=N/A | N=12 | Completed | Sponsor: Mayo Clinic | Recruiting ➔ Completed | N=94 ➔ 12

Enrollment change • Trial completion • Infectious Disease • Nephrology

Effect of Magnetic Nanoparticles on Hormone Level Changes During Perimenopausal Period and Regulation of Bone Metabolism. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "Rats in the estrogen treatment group were given Premarin suspension by gavage...Compared with the young control group, the humeral dry weight, wet weight, bone density, and bone mineral content, serum E2, OT, and BGP content in the perimenopausal period model group were reduced, while the serum BALP, CTX-I, and TRACP -5b content was increased (P<0.05). It was verified that nerve magnetic stimulation based on PTMP-MAA@ Fe3O4 NP increased the serum estrogen level of female rats during the perimenopausal period, increased the bone density of rats, promoted bone formation, and regulated bone metabolism."

Journal • Osteoporosis • Rheumatology • TRAP

[VIRTUAL] Improvement in OAB Symptoms After Vaginal Estrogen Therapy Is Associated with Measurable Pelvic Microbiome Changes (AUA 2020) - P=N/A, P4 | "Introduction: Improvement in OAB Symptoms After Vaginal Estrogen Therapy Is Associated with Measurable Pelvic Microbiome Changes Analysis of data from post-menopausal participants in two trials (NCT02524769 and NCT02835846) who chose vaginal estrogen as their primary OAB treatment and used 0.5 grams of Premarin Cream® twice weekly for 12 weeks. The mechanism of OAB symptom relief following vaginal estrogen use may relate to decreased microbial diversity. Following treatment, microbiota characteristics are more similar to a pre-menopausal state. Source of Funding: This study was funded by Loyola Urogynecology Division Research Fund, an Investigator Initiated grant from the Kimberly Clark Corporation, two NIH awards to Drs."

Late-breaking abstract • Gynecology